Cyclo Therapeutics, Inc (CYTH)

Etorro trading 970x250
Cyclo Therapeutics, Inc (CYTH) Logo

About Cyclo Therapeutics, Inc

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company’s lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida. Address: 6714 NW 16th Street, Gainesville, FL, United States, 32653

Cyclo Therapeutics, Inc News and around…

Latest news about Cyclo Therapeutics, Inc (CYTH) common stock and company :

Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
19 Oct, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today joins with the global Niemann-Pick Disease community in recognizing Niemann-Pick Disease Awareness Month, an initiative to build broader awareness of the impact this disease has on patients, families, and caregivers across the globe.

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
18 Oct, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstract has been selected for poster presentation at the upcoming 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held November 21-24, 2021 in Sydney, Australia and virtually.

Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
06 Oct, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will participate in the 2021 Virtual Cyclodextrin Conference hosted by CycloLab, “Cyclodextrins as active ingredients in the 21st century,” taking place on October 11, 2021.

Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
27 Sep, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund Kjems, MD, PhD as Chief Medical Officer. Gerald F. Cox, MD, PhD, who has served as the Company’s Acting Chief Medical Officer in a consultant role since March 2021, has been appointed to the Company’s Scientific Advisory Board (SAB).

Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
15 Sep, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow, PhD, Chief Scientific Officer and Senior Vice President for Medical Affairs of Cyclo Therapeutics, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET.

Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
17 Aug, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter of 2021, and provided a business update.

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
17 Aug, 2021 Yahoo! Finance

GAINESVILLE, Fla., August 17, 2021--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter of 2021, and provided a business update.

Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder
30 Jul, 2021 FinancialContent

Cyclo Therapeutics Inc(NASDAQ: CYTH)has announced new datafrom its Phase 1 extension study evaluating Trappsol ...

Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
30 Jul, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced new data from its Phase 1 extension study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (“NPC”), a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells. These data are being presented at the National Niemann Pick Disease Foundation Family Support & Medical Conference being held virtually July 29-August 1, 2021, and at the International Niemann Pick Disease Foundation biennial meeting held on August 1, 2021, also being held virtually.

Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
27 Jul, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has commenced the commercial-scale production of batches of Trappsol® Cyclo™, the Company’s proprietary formulation of hydroxypropyl beta cyclodextrin.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
22 Jun, 2021 FinancialContent

Gainers vTv Therapeutics (NASDAQ:VTVT) shares rose 30.08% to $3.07 during Tuesday's pre-market session. The ...

Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
21 Jun, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will present at the 2021 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 25-26, 2021.

Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
21 Jun, 2021 Yahoo! Finance

GAINESVILLE, Fla., Jun 21, 2021--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will present at the 2021 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 25-26, 2021.

Here's Why Some Shareholders May Not Be Too Generous With Cyclo Therapeutics, Inc.'s (NASDAQ:CYTH) CEO Compensation This Year
19 Jun, 2021 Yahoo! Finance

Performance at Cyclo Therapeutics, Inc. ( NASDAQ:CYTH ) has not been particularly rosy recently and shareholders will...

Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo
17 Jun, 2021 FinancialContent

Cyclo Therapeutics Inc(NASDAQ: CYTH)has commenced its pivotalPhase 3 study (TransportNPC) evaluating Trappsol Cyclo ...

Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
17 Jun, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the commencement of its pivotal Phase 3 study (“TransportNPC”) evaluating Trappsol® Cyclo™, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for the treatment of Niemann-Pick Disease Type C1 (NPC1). The TransportNPC study has the regulatory and IRB approval required to commence patient enrollment, and site activation is underway.

Cyclo Therapeutics Announces Launch of New Website
15 Jun, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced the launch of its new corporate website, cyclotherapeutics.com.

Cyclo Therapeutics Announces Launch of New Website
15 Jun, 2021 Yahoo! Finance

GAINESVILLE, Fla., Jun 15, 2021--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced the launch of its new corporate website, cyclotherapeutics.com.

12 Health Care Stocks Moving In Monday's After-Market Session
14 Jun, 2021 FinancialContent

Gainers RAPT Therapeutics (NASDAQ:RAPT) shares increased by 20.56% to $48.25 during Monday's after-market session. This security ...

Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
14 Jun, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Cyclo Therapeutics has been selected to be added to the Russell 2000® Index effective June 25, 2021, after the close of the U.S. equity markets.

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?
12 Jun, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
09 Jun, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that N. Scott Fine, Chief Executive Officer, Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President for Medical Affairs, and Gerald F. Cox, MD, PhD, Acting Chief Medical Officer of Cyclo Therapeutics will present at the virtual JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 12:30 PM ET.

12 Health Care Stocks Moving In Monday's Pre-Market Session
24 May, 2021 FinancialContent

Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market ...

12 Health Care Stocks Moving In Friday's Intraday Session
21 May, 2021 FinancialContent

Gainers Gracell Biotechnologies (NASDAQ:GRCL) shares rose 21.25% to $17.69 during Friday's regular session. Trading ...

Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
20 May, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced it will participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel on Wednesday, May 26, 2021 at 11:00 AM ET.

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
17 May, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today reported its financial results for the first quarter of 2021, and provided a business update.

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
17 May, 2021 Yahoo! Finance

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today reported its financial results for the first quarter of 2021, and provided a business update.

Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
11 May, 2021 FinancialContent

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, announced today it has appointed Lori McKenna Gorski as Global Head of Patient Advocacy.

55 Biggest Movers From Friday
03 May, 2021 FinancialContent

Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on ...

Cyclo Therapeutics, Inc (CYTH) is a NASDAQ Common Stock listed in , ,

970x250